Aclaris Therapeutics, Inc. (8AT.F)
| Previous close | 1.0580 |
| Open | 1.0785 |
| Bid | 1.0925 x 0 |
| Ask | 1.1410 x 0 |
| Day's range | 1.0785 - 1.0785 |
| 52-week range | 0.5900 - 11.8450 |
| Volume | |
| Avg. volume | 124 |
| Market cap | 79.337M |
| Beta (5Y monthly) | 0.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1800 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 34.80 |
PR NewswireFlare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately. Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, Ph
Simply Wall St.Favourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stock
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
ZacksAre Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
